<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02955173</url>
  </required_header>
  <id_info>
    <org_study_id>2016YFC0106003</org_study_id>
    <nct_id>NCT02955173</nct_id>
  </id_info>
  <brief_title>Significance of Circulating Tumor Cells in the Treatment of Gastric and Rectal Cancer</brief_title>
  <official_title>Significance of Circulating Tumor Cells (CTC) Detected by the CTCBIOPSY System as Potential Blood-based Biomarkers in Providing Prognostic and Predictive Information for Surgical Treatment of Gastric and Rectal Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Qilu Hospital of Shandong University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Peking University People's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Qilu Hospital of Shandong University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary purpose of this study is to compare both short-term and long-term treatment
      effect of laparoscopic vs. open approach on progressive gastric and rectal cancer, based on
      circulating tumor cell (CTC) test results as well as disease-free survivals, and figure out
      principles of laparoscopic approach for progressive gastric and rectal cancer. Secondary
      purpose is to establish an evaluation system for laparoscopic surgery for progressive gastric
      and rectal cancer treatment using CTC as a biomarker.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Laparoscopic surgery represents a milestone for treatment of gastric and rectal cancer, with
      advantages of minimal invasion and rapid recovery compared to open approach. However, for
      progressive gastric and rectal cancer, laparoscopic approach has not been officially promoted
      by NCCN guideline (2015).

      Over the past decade, circulating tumor cells (CTCs), originated from a tumor cell, have been
      identified as potential blood-based biomarkers capable of providing prognostic and predictive
      Information.

      In the present study, the investigators utilize the CTCBIOPSY® system (YZYBIO Company, Wuhan,
      China), which has been approved by CFDA (Chinese Food and Drug Administration), to detect
      CTCs, and try to compare both short-term and long-term treatment effect of laparoscopic vs.
      open approach on progressive gastric and rectal cancer, based on circulating tumor cell (CTC)
      test results as well as disease-free survivals, and figure out principles of laparoscopic
      approach for progressive gastric and rectal cancer. Secondary purpose is to establish an
      evaluation system for laparoscopic surgery for progressive gastric and rectal cancer
      treatment using CTC as a biomarker.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>December 2016</start_date>
  <completion_date type="Anticipated">December 2019</completion_date>
  <primary_completion_date type="Anticipated">December 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Screening</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Disease-free survival</measure>
    <time_frame>Two years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Circulating tumor cell (CTC) test</measure>
    <time_frame>Two years</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">600</enrollment>
  <condition>Circulating Tumor Cells</condition>
  <condition>Colorectal Cancer</condition>
  <condition>Gastric Cancer</condition>
  <arm_group>
    <arm_group_label>Open surgery of rectal cancer</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients undergoing rectal cancer resection in an open approach</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Laparoscopic surgery of rectal cancer</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients undergoing rectal cancer resection in a laparoscopic approach</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Open surgery of gastric cancer</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients undergoing gastric cancer resection in an open approach</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Laparoscopic surgery of gastric cancer</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients undergoing gastric cancer resection in a laparoscopic approach</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Surgery</intervention_name>
    <description>Laparoscopic or open surgery for resection of gastric or rectal cancer</description>
    <arm_group_label>Open surgery of rectal cancer</arm_group_label>
    <arm_group_label>Laparoscopic surgery of rectal cancer</arm_group_label>
    <arm_group_label>Open surgery of gastric cancer</arm_group_label>
    <arm_group_label>Laparoscopic surgery of gastric cancer</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Gastric cancer

        Inclusion Criteria:

          -  Gastric cancer of stage II/III

        Exclusion Criteria:

          -  History of malignant tumors

          -  Gastric cancer of stage Ⅳ

          -  Preoperative neoadjuvant chemotherapy

          -  History of upper abdominal surgery

          -  Severe other contradictions of surgery

        Rectal cancer

        Inclusion Criteria:

          -  Primary rectal carcinoma

          -  Single lesion

          -  No metastasis

          -  Sphincter-saving surgery available

        Exclusion Criteria:

          -  History of malignant tumors

          -  Acute bowel obstruction, bleeding or perforation

          -  Tumor over 6cm in diameter or in severe adhesion with surrounded tissues

          -  Severe other contradictions of surgery
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sanyuan Hu, M.D. Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Qilu Hospital of Shandong University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sanyuan Hu, M.D. Ph.D.</last_name>
    <phone>+86 18560086333</phone>
    <email>husanyuan1962@sdu.edu.cn</email>
  </overall_contact>
  <location>
    <facility>
      <name>Qilu Hospital of Shandong University</name>
      <address>
        <city>Jinan</city>
        <state>Shandong</state>
        <zip>250012</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sanyuan Hu, M.D. Ph.D.</last_name>
      <phone>+86 18560086333</phone>
      <email>husanyuan1962@sdu.edu.cn</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <link>
    <url>http://www.sda.gov.cn/WS01/CL0001/</url>
    <description>Website of Chinese Food and Drug Administration (CFDA)</description>
  </link>
  <link>
    <url>http://www.ctcbiopsy.com/</url>
    <description>Introduction of the CTCBIOPSY system</description>
  </link>
  <reference>
    <citation>Benson AB 3rd, Venook AP, Bekaii-Saab T, Chan E, Chen YJ, Cooper HS, Engstrom PF, Enzinger PC, Fenton MJ, Fuchs CS, Grem JL, Grothey A, Hochster HS, Hunt S, Kamel A, Kirilcuk N, Leong LA, Lin E, Messersmith WA, Mulcahy MF, Murphy JD, Nurkin S, Rohren E, Ryan DP, Saltz L, Sharma S, Shibata D, Skibber JM, Sofocleous CT, Stoffel EM, Stotsky-Himelfarb E, Willett CG, Gregory KM, Freedman-Cass D. Rectal Cancer, Version 2.2015. J Natl Compr Canc Netw. 2015 Jun;13(6):719-28; quiz 728.</citation>
    <PMID>26085388</PMID>
  </reference>
  <reference>
    <citation>Lowes LE, Bratman SV, Dittamore R, Done S, Kelley SO, Mai S, Morin RD, Wyatt AW, Allan AL. Circulating Tumor Cells (CTC) and Cell-Free DNA (cfDNA) Workshop 2016: Scientific Opportunities and Logistics for Cancer Clinical Trial Incorporation. Int J Mol Sci. 2016 Sep 8;17(9). pii: E1505. doi: 10.3390/ijms17091505.</citation>
    <PMID>27618023</PMID>
  </reference>
  <verification_date>February 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 2, 2016</study_first_submitted>
  <study_first_submitted_qc>November 3, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 4, 2016</study_first_posted>
  <last_update_submitted>February 8, 2017</last_update_submitted>
  <last_update_submitted_qc>February 8, 2017</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 9, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Qilu Hospital of Shandong University</investigator_affiliation>
    <investigator_full_name>Sanyuan Hu</investigator_full_name>
    <investigator_title>Dr.&amp; Prof.</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
    <mesh_term>Stomach Neoplasms</mesh_term>
    <mesh_term>Rectal Neoplasms</mesh_term>
    <mesh_term>Neoplastic Cells, Circulating</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

